ANALYSIS OF PRINCIPLES FOR IMPROVING OPTIMAL TREATMENT MEASURES FOR LIVER AND BILE DUCT DISEASES

A chronic autoimmune liver disease called primary biliary cholangitis (PBC) is characterized by the destruction of the bile duct, which results in fibrosis and cholestasis. There are still gaps in patient-centered care, therapy response evaluation, and diagnostic standardization despite therapeutic breakthroughs. The goal of this study was to optimize PBC management by using consensus-driven quality measures. 92 clinicians took part in two rounds of questionnaires that included patient-reported outcomes (PROs), follow-up criteria, therapeutic approaches, and diagnostic methods using the Delphi methodology. The RAND/UCLA technique was used to analyze appropriateness evaluations in order to get a consensus on important quality metrics.The suitability of non-invasive diagnostic techniques such abdominal ultrasound and Vibration-Controlled Transient Elastography (VCTE) for staging and tracking fibrosis in chronic cholestasis was widely agreed upon. Patients with compensated cirrhosis (Child-Pugh A) and inadequate response to UDCA were investigated for various treatment options; early initiation was considered appropriate in cases of UDCA intolerance or partial response. Consensus on genetic tests and liver biopsies varied, especially for patients lacking biochemical cholestasis, indicating areas that require more investigation. This study provides detailed suggestions on diagnostic procedures, therapy benchmarks, and follow-up requirements in order to establish practical quality measurements for PBC care. By filling in gaps in patient categorization, follow-up procedures, and tactics, these actions go above and beyond recommendations. Cost-effectiveness, non-invasive tool accessibility, and implementation issues including physician training and resource availability should all be covered in future studies.